Site-specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT-351) with technetium-99m

European Journal of Nuclear Medicine

Volumn 24, Issue 6, 1997, Pages 651-654

  Stalteri, Maria A ^a   Mather, Stephen J ^a   Belinka, Benjamin A ^b   Coughlin, Daniel J ^b   Chengazi, Vaseem U ^a   Britton, Keith E ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b Cytogen Corporation   (United States)

Author keywords

Monoclonal antibody; Prostate cancer; Radioimmunoscintigraphy; Radiolabelling; Technetium 99m

Indexed keywords

CHELATING AGENT; CYSTEINE; LYSINE; MERCAPTOETHANOL; MONOCLONAL ANTIBODY; TECHNETIUM 99M;

ANTIBODY COMBINING SITE; ANTIBODY LABELING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONJUGATION; HALF LIFE TIME; HUMAN; IMMUNOREACTIVITY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; PLASMA CLEARANCE; PROSTATE; PROSTATE CANCER; PROVOCATION TEST;

EID: 0030793048     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00841403     Document Type: Article

References (8)

1. Rodwell JD, Alvarez VL, Lee C, Lopes AD, Goers JWF, King DH, Powsner HJ, McKearn TJ. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986;83:2632-2636.
2. Coughlin DJ, Belinka BA Jr. Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding. 1994, US Patent no. 5,326,856.
3. Feneley MR, Chengazi VU, Kirby RS, Nimmon CC, Granowska M, Mather SJ, Ellison D, Granowski AR, Britton KE. Prostatic radioimmunoscintigraphy: preliminary results using technetium-labelled monoclonal antibody, CYT-351. Br J Urol 1996;77:373-381.
4. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7: 927-936.
5. Mather SJ, Ellison D. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med 1990;31: 692-697.
6. 99mTc-labeled antibodies? Nucl Med Biol 1994;21: 1035-1044.
7. Abraham R, Moller D, Gabel D, Senter P, Hellstrom I, Hellstrom KE. The influence of periodate oxidation on monoclonal antibody avidity and immunoreactivity. J Immunol Methods 1991;144:77-86.
8. Chengazi VU, Feneley, MR, Mather SJ et al. Imaging prostate cancer with the monoclonal radioimmunoconjugate technetium-99m-7E11-C5.3 (CYT-351). J Nucl Med 1997; in press.